Navigation Links
DNA Exonuclease III , E. coli from EPICENTRE Biotechnologies

ProductsDNA Exonuclease III , E. coli from EPICENTRE Biotechnologies
Company EPICENTRE Biotechnologies
Item DNA Exonuclease III , E. coli
Price $48.00
Description Exonuclease III digests duplex DNA in a 3'-> 5' direction from a blunt end, 5'-overhang or nick, producing stretches of single-stranded DNA. Under defined reaction conditions, DNA degradation by Exonuclease III proceeds at a uniform rate yielding predictable and reproducible results. Because the rate of exonucleolytic excision of deoxyribonucleotides by Exonuclease III is dependent upon reaction factors including temperature, ionic strength, template sequence, and enzyme-to-DNA ratios, each template must be optimized using sample digestions to achieve the desired excision rate. Exonuclease III is not active on 3'-protruding ends of 4 bases or more in length, single-stranded DNA, or on thioester-linked nucleotides. The enzyme also has intrinsic RNase H, 3'-DNA phosphatase, and apurinic DNA endonuclease activities.
Info EPICENTRE BiotechnologiesEPICENTRE Biotechnologies
726 Post Road
Madison, WI 53713
USA
Customer Service: 800-284-8474
Tech Support: 800-284-8474
Fax Number: 608-442-6114
Web Site: http://www.epibio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Klenow Fragment, Exonuclease Minus from Promega
2. Exonuclease III from Promega
3. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
4. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
5. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
6. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
7. GELase LMT Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
8. GELase LMT Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
9. GELase LMT Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
10. EZ-Tn5 Transposase from EPICENTRE Biotechnologies
11. DNA Polymerase I, E. coli from EPICENTRE Biotechnologies
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
...
Biology Products:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... , February 27, 2017 A Europe-wide survey ... that researchers using animals in their research treat them with due ... countries, and detailed analysis of the results indicates that there is ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... SAN FRANCISCO , Feb. 27, 2017 ... Spain has been appointed as ... Biopsy System. The IsoFlux system will be used in ... mutations relevant to lung and colon cancer, with plans ... developed. The laboratory is utilizing Fluxion,s IsoFlux System to ...
(Date:2/24/2017)... ... February 24, 2017 , ... A ... safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported ... two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on the ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
Breaking Biology Technology: